Drug
Recombinant Human Papillomavirus Bivalent (Types 16, 18) Vaccine (Escherichia coli)
Recombinant Human Papillomavirus Bivalent (Types 16, 18) Vaccine (Escherichia coli) is a pharmaceutical drug with 4 clinical trials. Currently 1 active trials ongoing.
Total Trials
4
Max Phase
—
Type
DRUG
Molecule
—
Success Metrics
Active Trials
1(25%)
Phase Distribution
No phase data available
Trial Status & Enrollment
Completion Rate
0.0%
0 of 0 finished
Non-Completion Rate
0.0%
0 ended early
Currently Active
1
trials recruiting
Total Trials
4
all time
Status Distribution
Active(1)
Other(3)
Detailed Status
unknown3
Active, not recruiting1
Development Timeline
Analytics
Development Status
Total Trials
4
Active
1
Success Rate
N/A
Trials by Status
unknown375%
active_not_recruiting125%
Recent Activity
1 active trials
Showing 4 of 4
active_not_recruiting
Long-term Effectiveness and Immuno-persistence Study of a Recombinant HPV 16/18 Bivalent Vaccine in Preadolescent Girls
NCT06243666
unknown
The Durability of Protection Study of a Recombinant HPV 16/18 Bivalent Vaccine in Female
NCT04969445
unknown
The Durability of Protection and Immuno-persistence Study of a Recombinant HPV 16/18 Bivalent Vaccine in Female
NCT05045755
unknown
Immuno-persistence Study of a Recombinant Human Papillomavirus 16/18 Bivalent Vaccine in Preadolescent Girls (54m)
NCT04704908
Clinical Trials (4)
Showing 4 of 4 trials
NCT06243666
Long-term Effectiveness and Immuno-persistence Study of a Recombinant HPV 16/18 Bivalent Vaccine in Preadolescent Girls
NCT04969445
The Durability of Protection Study of a Recombinant HPV 16/18 Bivalent Vaccine in Female
NCT05045755
The Durability of Protection and Immuno-persistence Study of a Recombinant HPV 16/18 Bivalent Vaccine in Female
NCT04704908
Immuno-persistence Study of a Recombinant Human Papillomavirus 16/18 Bivalent Vaccine in Preadolescent Girls (54m)
All 4 trials loaded
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 4